reg ululls, is micronase. you have a new pool of targets that have been not been addressed before, as a basis for developing new drugs, and you add that to the complexity of new chemical entities that interact. so we like that. that's the core of any biotech innovative company. that's how we think, if you take those risks, the rewards will be great. so what we saw today is not only the reaction to the rg-101, the help tights-c compound, but validation of the entire fro platform. >> in terms of who you are tack talking about, because they don't have a core interest in hep-c, would it be gilead? >> basically if you look at the top four companies in the space competing for a market space, in fact 5, i would name gilead, merck, and j & j, those are all potential companies that we can attempt to combine rg-101 with some of their medicines to maximize the outpit for the hepatitis-c patients. >> thank you for your time. we appreciate it. >> thank you very much. >>> quickly, meg, in terms of your reaction. you made a